Deregulation of Lipid Metabolism: The Critical Factors in Ovarian Cancer

Frontiers in Oncology

Gong Yang²  Xiaofei Zhang³  Yue Kong⁴  Jiao Meng⁴  Xu Feng⁴  Yang Shao⁴  Zhaodong Ji⁴  Yan Shen⁵ 

[1] Cancer Institute, Fudan University Shanghai Cancer Center, Shanghai, China;Central Laboratory, The Fifth People’s Hospital of Shanghai Fudan University, Shanghai, China;Department of Gynecology, Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine, Shanghai, China;Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China;Department of Pharmacy, Nantong Health College of Jiangsu Province, Nantong, China;

关键词: ovarian cancer;    lipid metabolism;    potential target;    fatty acid synthesis;    metabolic enzyme;   

DOI  :  10.3389/fonc.2020.593017

来源: DOAJ

【 摘 要 】

Ovarian cancer is one of the most malignant gynecological cancers around the world. In spite of multiple treatment options, the five-year survival rate is still very low. Several metabolism alterations are described as a hallmark in cancers, but alterations of lipid metabolism in ovarian cancer have been paid less attention. To explore new markers/targets for accurate diagnosis, prognosis, and therapeutic treatments based on metabolic enzyme inhibitors, here, we reviewed available literature and summarized several key metabolic enzymes in lipid metabolism of ovarian cancer. In this review, the rate limiting enzymes associated with fatty acid synthesis (FASN, ACC, ACLY, SCD), the lipid degradation related enzymes (MAGL, CPT, 5-LO, COX2), and the receptors related to lipid uptake (FABP4, CD36, LDLR), which promote the development of ovarian cancer, were analyzed and evaluated. We also focused on the review of application of current metabolic enzyme inhibitors for the treatment of ovarian cancer through which the potential therapeutic agents may be developed for ovarian cancer therapy.

【 授权许可】

Unknown